Dutch biotechnology firm Crucell has been awarded an additional contract totaling over $20.0 million for its Quinvaxem pediatric vaccine. This contract was awarded by a supranational organization for Latin America and covers sales in 2007.
This contract is valid for 2007 and is in addition to the that which was awarded to Crucell earlier this month by supranational organizations totaling over $230.0 million for both its Quinvaxem and Hepavax-Gene pediatric vaccines representing minimum sales to these supranational organizations over the next three years including 2009 (Marketletter December 11). Current worldwide demand for Quinvaxem exceeds 50 million doses anually, and the market potential is 150 million doses a year in three to four years time, the firm states.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze